JPRN-jRCT2080221241未知2 期
A Phase IIa Study of Z-207 in Patients with Seasonal Allegic Rhinitis - Investigation of the Efficacy and Safety of Z-207 after Single Injection
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 64age old（—）
- 性别
- All
入选标准
- •Patient with history of moderate to sever seasonal allergic rhinitis for at least 2 years
- •Patient with positive reaction for Radio Allergen Sorbent Test using Japanease ceder pollen
- •Patient exhibit both a total nasal symptom score of at least 4, and a nasal obstruction score of at least 2 under exposure to allergen using pollen challenge chamber ( Total nasal symptom score is the sum of sneezing, nasal discharge, nasal obstruction which has been scored on a scale from 0 to 4 )
排除标准
- •Patient with positive reaction for Radio Allergen Sorbent Test for house dust mite
- •Patient with positive reaction for Radio Allergen Sorbent Test for orchard grass pollen
- •Patient who never received medical drug therapy for allergic rhinitis
研究者
相似试验
进行中（未招募）
1 期
Phase II Study of ZK 219477 in patients with recurrent glioblastomaEUCTR2006-001659-37-GBEuropean Organisation for Research and Treatment of Cancer
进行中（未招募）
1 期
Phase II Study of ZK 219477 in patients with recurrent glioblastomaPhase II study of ZK 219477 in patients with recurrent glioblastoma.MedDRA version: 8.1Level: LLTClassification code 10018336Term: GlioblastomaEUCTR2006-001659-37-DEEuropean Organisation for Research and Treatment of Cancer
进行中（未招募）
1 期
Phase II Study of ZK 219477 in patients with recurrent glioblastomaPhase II study of ZK 219477 in patients with recurrent glioblastoma.MedDRA version: 8.1Level: LLTClassification code 10018336Term: GlioblastomaEUCTR2006-001659-37-NLEuropean Organisation for Research and Treatment of Cancer
进行中（未招募）
1 期
Phase II Study of ZK 219477 in patients with recurrent glioblastomaEUCTR2006-001659-37-FREuropean Organisation for Research and Treatment of Cancer
未知
1 期
Phase I Clinical Study of RG7167 in Patients with Advanced Solid TumorsJPRN-jRCT2080221451Chugai Pharmaceutical Co., Ltd.36